No Data
Bright Minds Biosciences to Present at Key Healthcare Conferences and Grants Equity Incentives
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Bright Minds Biosciences Advances Epilepsy Treatment With BMB-101 Study
'Psychedelics Show Promise As An 'Entirely New Type Of Anti-Inflammatory Treatment,' Research Suggests' - Marijuana Moment
'New York Lawmakers Hold Hearing Psilocybin's Medical Benefits Amid Broader Debate Over Psychedelics Reform' - Marijuana Moment
BTIG Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $72